Heron Therapeutics (HRTX) CEO Craig Collard Converts 84,810 RSUs

What Happened

• Craig A. Collard, Chief Executive Officer of Heron Therapeutics (HRTX), converted a total of 84,810 derivative units into common shares in two transactions: 50,021 on July 30, 2026 and 34,789 on July 31, 2026. Each conversion is reported as a derivative transaction (Form 4 code M). The converted shares are shown as disposed at $0.00, meaning no cash proceeds were received in these reported disposals.

Key Details

• Transaction dates & amounts:
  • 2026-07-30: 50,021 shares — conversion reported; disposed at $0.00.
  • 2026-07-31: 34,789 shares — conversion reported; disposed at $0.00.
• Price/proceeds: Disposed at $0.00 in the filing (no open-market sale proceeds recorded).
• Shares owned after transaction: Not specified in the provided filing details.
• Filing date and timeliness: Form filed 2026-08-03. Based on the transaction dates, the filing appears timely (filed on the SEC filing date shown).
• Footnotes from the filing:
  • F1: Each restricted stock unit (RSU) represents a contingent right to one share.
  • F2: On Jan 30, 2026 the reporting person was granted 800,337 RSUs vesting in 16 equal quarterly installments; the full grant is disclosed.
  • F3: Notes the RSUs vest in 16 equal installments beginning one quarter after grant; the filing also includes a date (Jan 31, 2025) that appears inconsistent with the Jan 30, 2026 grant date.

Context

• The transactions are reported as conversions/exercises of derivative securities (code M) tied to RSUs. The zero-dollar disposal entries are consistent with shares being withheld or transferred to satisfy tax withholding or similar obligations upon vesting rather than an open-market sale; the filing itself does not show cash proceeds or an open-market sale. These conversions reflect scheduled vesting from the previously disclosed RSU grant rather than a purchased or sold position driven by market trades.